Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3120 participants.

Also called NCT07939516

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,120 participants (planned count) (from the registry)
Sponsor
Medisch Spectrum Twente (from the registry)
Registry
  • NCT NCT07939516
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07939516. Randomized; no masking; primary purpose treatment. Start 2026-11-15 (anticipated); primary completion 2029-11-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Acronym
IGNITION
Condition
Acute Coronary Syndromes (ACS)
Condition
Unstable Angina Pectoris
Condition
Myocardial Infarction (MI)
Condition
STEMI
Condition
NSTEMI
Intervention (Drug)
Genotype guided P2Y12 therapy
Intervention (Drug)
Standard therapy group
Lead sponsor
Medisch Spectrum Twente (class: other)
Collaborator
Ziekenhuisgroep Twente (class: other)

Record details

Record id
cardio:ct-nct07939516
Content hash
db85ec7ec0dd502682f668cd135ec291b60fe5d97c628cd51932ccd4e3ecb52a